An interventional study of continuous peripheral nerve block in Knee Arthropathy, sponsored by Policlinico di Monza SpA. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Policlinico di Monza SpA · Not applicable, Interventional, and Prevention
Patients undergone total knee replacement are randomized to receive a "fast track" regional anesthesia protocol or a "traditional" regional anesthesia continuous infusion by both a femoral and sciatic catheter to assess if this latter technique may reduce persistent postoperative pain six months after surgery
Patients undergone to primary total knee replacement with spinal anesthesia are randomized to receive a continuous adductor canal block infusion + an ipack block or a continuous femoral nerve block + a continuous sciatic nerve block just at the end of surgery. Both group will receive a multimodal analgesia with paracetamol, ketorolac, desametasone and morphine as a rescue.
5,093 studies on the registry are indexed under Pain, Postoperative; 1,137 are open to participants now.
This study's planned enrollment of 436 is above the median of 75 across 4,341 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →This is the only study on the registry with Policlinico di Monza SpA as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
continuous adductor canal block and ipack block
Procedure: continuous peripheral nerve block
continuous femoral nerve block and continuous sciatic block
Procedure: continuous peripheral nerve block
continuous regional anesthesia in total knee replacement
Persistent post surgical pain
Numeric rating score (0-10) over 4 at the follow up 6-month after total knee replacement
Time frame: 0-6-month
acute postoperative pain
Numeric rating score (0-10) over 4 in POD0, POD1, POD2, POD3
Time frame: 0-72 hours
Morphine requirement
total morphine administration via PCA in POD0, POD1, POD2, POD3
Time frame: 0-72 hours
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.